• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

A bottom-line case for moving your lens finishing in-house

Article

Spectacle lens sales, excluding frames, generate about the same annual revenue as eye exams, yet are often an afterthought for many busy practices.

Spectacle lens sales, excluding frames, generate about the same annual revenue as eye exams, yet are often an afterthought for many busy practices. Adding in-office finishing can help maximize revenues, Mike Rothschild, OD, said.

Although two-thirds of patients see an optometrist for eye exams, three or four out of every 10 leave the office to purchase eyewear elsewhere, according to Dr. Rothschild. "In a practice with $750,000 annual gross revenue and an average eyewear capture rate of 61%, $160,000 in revenue walks out the door each year," he said.

Factors to consider

Compare the costs of the outsourcing business model to those of the in-office model by calculating monthly outsourcing costs, in-office finishing costs, insurance reimbursements, and in-office finishing savings. The result will be an estimate of the annual margin from in-office finishing.

In the financial analysis, remember to balance the cost of a major purchase, such as an edger, with new revenue. But generating that new revenue will cost money, and the formula doesn't work if both inputs are equal. Dr. Rothschild recommended that you plan to generate up to twice as much revenue as any new expense-$1,500 to $2,000 in revenue for a $1,000 cost.

Related Videos
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Shelley Cutler, OD, FAAO, outlines her key takeaways from this year's IKA symposium
© 2024 MJH Life Sciences

All rights reserved.